Background:The aim of the present study was to investigate the effects of heparin on in vitro stimulated platelet aggregation by elective percutaneous coronary intervention Methods: Thirty elective percutaneous coronary angioplasty (PTCA) patients were included in the present study. The patients were administered heparin as anticoagulant agent during PTCA. Two blood samples were obtained during the intervention before and 10 minutes after heparin bolus and stimulated platelet aggregation responses were investigated.
Results:The difference in platelet aggregation response to adenosine diphosphate (ADP) before and after unfractionated heparin (UFH) was statistically significant (p<0.05). The differences in platelet aggregation responses to collagen, to epinephrine, and to ristocetin before and after UFH were not statistically significant (p>0.05).
Conclusion: Heparin increases in vitro plateletaggregation stimulated with ADP in elective PTCA patients. This finding might explain the prothrombotic tendency of heparin, however further investigations are needed.
Aim:The aim of the present study was to investigate the effects of enoxaparin on in vitro stimulated platelet aggregation by elective percutaneous coronary intervention patients.
Method:Twenty-two patients that scheduled for elective percutaneous coronary angioplasty (PTCA) were enrolled in the present study. The patients who had not been taking any antiaggregant agent other than aspirin and normal platelet account received enoxaparin (1mg/kg IV bolus) as anticoagulant agent during PTCA. Two blood samples were obtained for every patient via femoral arterial sheath during the intervention before and 10 minutes after enoxaparin administration and stimulated platelet aggregation responses are investigated.
Results:The decrease in platelet aggregation responses to adenosine diphosphate (ADP), collagen and epinephrine before and after enoxaparin administration were statistically significant (p<0.05). The decrease in platelet aggregation response to ristocetin before and after enoxaparin was not statistically significant (p>0.05).
Conclusion:Enoxaparin may reduce platelet aggregation in elective PTCA patients pretreated with aspirin only.With the knowledge of the importance of the platelet inhibition, choice of the anticoagulant agent during PTCA may be beneficial.Keywords: Enoxaparin, stimulated platelet aggregation, elective PTCA Abstract EJCM 2017; 05 (2):
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.